eXoZymes, Inc.
EXOZHealthcare|Biotechnology|US
$4.40
+0.29 (+7.06%)
DCF Value
$0.14
Tangible Book / Share
$0.42
Cash / Share
$0.65
Financials
Financial Snapshot
Market Cap
$40.8M
Enterprise Value
$36.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.2M
Cash & Investments
$5.7M
Net Cash
$4.6M
Free Cash Flow (TTM)
-$7.1M
Operating CF (TTM)
-$7.0M
Debt/Equity
0.30
Cash Runway & Burn Rate
Cash on Hand
$5.7M
Quarterly Burn
$1.7M
Monthly Burn
$582.9K
Est. Runway
~3.2 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $547.8K | $558.6K | $66.5K | $9.7M | $3.0M | $5.7M | |
| Operating Cash Flow | -$1.6M | -$1.3M | -$1.2M | -$8.5M | -$6.5M | -$7.0M | |
| Free Cash Flow | -$2.0M | -$1.4M | -$1.5M | -$8.9M | -$6.7M | -$7.1M | |
| Capital Expenditure | -$422.6K | -$186.0K | -$288.7K | -$396.5K | -$169.9K | -$145.9K | |
| Financing Cash Flow | $2.3M | $1.4M | $1.0M | $18.5M | -$27.7K | $5.8M |
R&D Spending
R&D (TTM)
$4.9M
R&D Intensity
—
R&D Growth vs Prior
+31.9%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $454.5K | $348.1K | $527.5K | $1.9M | $3.7M | $4.9M | |
| SG&A | $779.0K | $836.8K | $1.3M | $3.8M | $5.9M | $5.5M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $59.4K | $147.8K | $0.00 | $267.4K | $0.00 | -$68.6K | |
| Gross Profit | -$59.4K | -$147.8K | $0.00 | -$267.4K | $0.00 | $68.6K | |
| R&D | $454.5K | $348.1K | $527.5K | $1.9M | $3.7M | $4.9M | |
| SG&A | $779.0K | $836.8K | $1.3M | $3.8M | $5.9M | $5.5M | |
| Operating Income | -$1.3M | -$1.3M | -$1.8M | -$5.9M | -$9.7M | -$10.6M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$1.2M | -$1.3M | -$2.0M | -$5.9M | -$9.3M | -$10.3M | |
| Net Income | -$1.2M | -$1.4M | -$2.0M | -$5.9M | -$9.2M | -$10.2M | |
| EPS (Diluted) | -0.15 | -0.17 | -0.25 | -0.72 | -1.09 | -1.20 | |
| EBITDA | -$1.1M | -$1.2M | -$1.8M | -$5.6M | -$9.0M | -$10.5M | |
| Shares Out. (M) | 8.13 | 8.13 | 8.13 | 8.13 | 8.38 | 8.66 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $547.8K | $558.6K | $66.5K | $9.7M | $3.0M | $5.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $1.0M | $1.5M | $1.2M | $10.8M | $3.9M | $6.2M | |
| Total Assets | $2.3M | $2.7M | $3.6M | $13.0M | $6.0M | $8.0M | |
| Total Current Liabilities | $400.8K | $634.4K | $2.4M | $1.3M | $1.6M | $1.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.1M | $1.3M | $3.9M | $2.6M | $2.6M | $4.3M | |
| Stockholders' Equity | $1.2M | $1.4M | -$384.3K | $10.4M | $3.4M | $3.7M | |
| Retained Earnings | -$2.7M | -$4.0M | -$6.1M | -$11.9M | -$21.1M | -$26.4M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6M | -$1.3M | -$1.2M | -$8.5M | -$6.5M | -$7.0M | |
| Capital Expenditure | -$422.6K | -$186.0K | -$288.7K | -$396.5K | -$169.9K | -$145.9K | |
| Free Cash Flow | -$2.0M | -$1.4M | -$1.5M | -$8.9M | -$6.7M | -$7.1M | |
| Investing Cash Flow | -$312.3K | -$87.2K | -$311.2K | -$359.2K | -$150.2K | -$145.9K | |
| Financing Cash Flow | $2.3M | $1.4M | $1.0M | $18.5M | -$27.7K | $5.8M | |
| Issuance of Stock | $2.3M | $1.4M | $0.00 | $14.5M | $0.00 | $5.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $4.0M | -$27.7K | -$15.0K | |
| Stock Based Comp. | $198.5K | $216.5K | $281.5K | $1.1M | $2.0M | $2.8M | |
| Net Change in Cash | $413.4K | $10.8K | -$492.0K | $9.7M | -$6.7M | -$1.3M |
Dilution Tracker
Shares Outstanding
9M
5-Year Share Growth
+3.1%
Stock Issuance (TTM)
$5.9M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 8.13 | 8.13 | 8.13 | 8.13 | 8.38 | 8.66 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | 3.1% | 3.3% | |
| Stock Issuance | $2.3M | $1.4M | $0.00 | $14.5M | $0.00 | $5.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $198.5K | $216.5K | $281.5K | $1.1M | $2.0M | $2.8M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | -101.0% | -101.7% | 530.4% | -56.2% | -269.6% | -292.1% | |
| ROA % | -51.5% | -52.0% | -57.3% | -45.0% | -153.4% | -127.7% | |
| ROIC % | -62.2% | -60.7% | -131.3% | -49.7% | -203.1% | -155.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -148.7% | 100.0% | 0.0% | 100.0% | |
| Operating Income | 0.0% | -3.1% | -34.8% | -230.3% | -63.8% | |
| Net Income | 0.0% | -15.5% | -46.0% | -187.5% | -56.3% | |
| EPS (Diluted) | 0.0% | -13.3% | -47.1% | -188.0% | -51.4% | |
| Operating Cash Flow | 0.0% | 20.8% | 6.1% | -620.3% | 23.6% | |
| Free Cash Flow | 0.0% | 28.2% | -1.8% | -505.8% | 25.1% | |
| R&D Expense | 0.0% | -23.4% | 51.5% | 254.3% | 98.4% | |
| SG&A Expense | 0.0% | 7.4% | 60.0% | 183.5% | 55.8% | |
| Total Assets | 0.0% | 14.5% | 32.5% | 266.3% | -54.2% | |
| Book Value / Share | 0.0% | 14.7% | -128.0% | 2811.5% | -68.4% | |
| Debt | 0.0% | -15.5% | 164.8% | -14.0% | -10.4% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 3.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B10.43
10Y Low / Med / High12.87 / 51.22 / 58.73
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.14
Tangible Book / Share
$0.42
Net Current Assets / Share
$0.20
Graham Net-Net
$0.17
Cash / Share
$0.65
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -57.67 | -50.88 | -34.60 | -22.92 | -10.00 | -3.67 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 58.73 | 51.22 | -182.93 | 12.87 | 26.89 | 10.43 | |
| EV/EBITDA | -61.30 | -59.38 | -39.93 | -22.48 | -9.98 | -3.45 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-2.74
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $540.0K | $4.8M |
| Net Income | -$10.0M | -$9.4M | -$3.9M |
| EPS | $-1.19 | $-1.12 | $-0.47 |
| # Analysts (EPS) | 1 | 1 | 1 |